Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrzej Lutynski

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
The American Journal of Medicine|July 31, 2010
Malignant mimicrySharmistha Mishra, Danny Ghazarian, Andrzej Lutynski, et al.
Cytometry. Part B, Clinical Cytometry|September 16, 2006
Flow cytometric assessment of autologous gammadelta T cells in patients with acute myeloid leukemia: potential effector cells for immunotherapy?Jorg M Aswald, Xing-Hua Wang, Sandra Aswald, et al.
European Journal of Clinical Pharmacology|March 19, 2005
The pharmacokinetics of erythropoietin in the cerebrospinal fluid after intravenous administration of recombinant human erythropoietinAnargyros Xenocostas, Wing K Cheung, Francis Farrell, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|October 21, 2018
A phase II open-label study of aprepitant as anti-emetic prophylaxis in patients with acute myeloid leukemia (AML) undergoing induction chemotherapyJoseph M Brandwein, Jack T Seki, Eshetu G Atenafu, et al.
Leukemia & Lymphoma|June 10, 2017
Remissions after third induction chemotherapy for primary non-responders with acute myeloid leukemia (AML) are uncommon and short-livedSara Farshchi Zarabi, Steven Chan, Vikas Gupta, et al.
Leukemia Research|March 9, 2018
AML refractory to primary induction with Ida-FLAG has a poor clinical outcomeSimon Kavanagh, Emily Heath, Rose Hurren, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
The American Journal of Medicine|July 31, 2010
Malignant mimicrySharmistha Mishra, Danny Ghazarian, Andrzej Lutynski, et al.
Cytometry. Part B, Clinical Cytometry|September 16, 2006
Flow cytometric assessment of autologous gammadelta T cells in patients with acute myeloid leukemia: potential effector cells for immunotherapy?Jorg M Aswald, Xing-Hua Wang, Sandra Aswald, et al.
European Journal of Clinical Pharmacology|March 19, 2005
The pharmacokinetics of erythropoietin in the cerebrospinal fluid after intravenous administration of recombinant human erythropoietinAnargyros Xenocostas, Wing K Cheung, Francis Farrell, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|October 21, 2018
A phase II open-label study of aprepitant as anti-emetic prophylaxis in patients with acute myeloid leukemia (AML) undergoing induction chemotherapyJoseph M Brandwein, Jack T Seki, Eshetu G Atenafu, et al.
Leukemia & Lymphoma|June 10, 2017
Remissions after third induction chemotherapy for primary non-responders with acute myeloid leukemia (AML) are uncommon and short-livedSara Farshchi Zarabi, Steven Chan, Vikas Gupta, et al.
Leukemia Research|March 9, 2018
AML refractory to primary induction with Ida-FLAG has a poor clinical outcomeSimon Kavanagh, Emily Heath, Rose Hurren, et al.
Pageof 1